Navigation Links
Amsterdam Molecular Therapeutics Reports Full Year Results 2009
Date:2/24/2010

AMSTERDAM, February 24, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year to December 31, 2009.

    Highlights
    - Glybera(R) Marketing Authorisation Application submitted to
      European Medicines Agency (EMA, formerly known as EMEA);
    - EMA commenced formal review of Glybera(R) dossier on January
      20, 2010;
    - EMA grants orphan drug designation for AMT's Acute
      Intermittent Porphyria ("AIP") program;
    - EMA grants orphan drug designation for AMT's Duchenne
      Muscular Dystrophy ("DMD") program;
    - SenterNovem awards EUR 4 million investment credit for the
      development of AMT's DMD program;
    - Raised EUR 5 million convertible loan notes, which convert
      into ordinary shares at EUR 3.91 per share;
    - New management team.

Jorn Aldag, Chief Executive Officer of AMT, commented: "In 2009 we announced a rebalancing of our strategy, focused on our lead product Glybera(R), a proprietary product for lipoprotein lipase deficiency (LPLD), together with the ongoing development of four earlier stage progams targeting:
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
2. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
3. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
5. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
6. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
7. Amsterdam Molecular Therapeutics Part of Next Biotech Index
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
11. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 On January, 14, 2015, ... Washington D.C. science community to the UMBC campus for ... by the Protein Society, will take place from 9 ... 312. Through discussion, presentations and workshops, the free ... proteins, their role in the industry and the future ...
(Date:11/26/2014)... Sunnyvale, CA (PRWEB) November 25, 2014 ... joins forces with RPM Alliance , provider ... and pharmaceutical companies. With the latest addition to its ... only free validated EDC system to India. , ... as a robust and customizable EDC platform which is ...
(Date:11/26/2014)... November 26, 2014 SoundConnect , ... is proud to announce that Darren Suders has joined ... Darren will drive the partner program ... experience. , Darren brings more than 10-years ... key roles in channel operations, from policy development, to ...
(Date:11/26/2014)... 25 novembre 2014 /PRNewswrie/ -- Theravalues Corporation annuncia con ... europeo in occasione di Hi Europe 2014 (dal 2 ... Si tratta della curcumina con la maggiore biodisponibilità ... cristalli) e ingredienti approvati dalle norme europee. ... della pianta curcumina ( Curcuma longa ) che è ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3
... , , WATERTOWN, Mass., Sept. 10 ... breakthrough synthetic chemistry technology announced today that it will ... on the synthesis and antibacterial activity of analogs from ... at the 49th Interscience Conference on Antimicrobial Agents and ...
... STOCKHOLM, September 10 Pergamum AB has announced ... wound healing interests, and create a broad-based therapeutic ... The Pergamum product pipeline consists of five ... Indications covered within the,portfolio include improved wound healing ...
... , , , ... Inc. (PTC) today announced the initiation of a Phase 3 ... in patients with nonsense mutation cystic fibrosis (nmCF). Patients ... conductance regulator (CFTR) protein, a chloride channel necessary for normal ...
Cached Biology Technology:Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009 2Pergamum to Provide Effective Development of Innovative Dermatology and Wound Healing Companies 2PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 2PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 3PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 4PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 5PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 6
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
(Date:11/7/2014)... professor, biomedical engineering, in the Grove School of ... have identified a molecule that could lead to ... forms of breast cancer. , Triple negative breast ... to aggressive proliferation and metastasis and a lack ... discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) ...
(Date:11/6/2014)... predator. Except when that predator runs so fast that it ... size, is the fastest creature on Earth. Some of these ... about five miles per hour). The fastest human can do ... the tiger beetle, a person would have to hit 480 ... problem. At peak speeds, everything becomes a blur. They can,t ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3The tiger beetle: Too fast to see 2
... novel method of collecting and storing carbon dioxide that will ... The quest to capture carbon dioxide is crucial to ... compressed and safely stored. It is also a ... and require several stages of refining and extraction before a ...
... antibiotic and anti-cancer chemicals may one day be synthesised ... that combine to provide soldier beetles with their potent ... Sweden,s Karolinska Institute, published details of the gene identification ... Nature Communications ., "For the first time, our ...
... skin and well-armored bodies. So it comes as something of a ... the most acute in the animal kingdom. The crocodilian sense ... that dot their skin all over their body. In alligators, the ... study, published in the Nov. 8 issue of the Journal ...
Cached Biology News:Capturing carbon with clever trapdoors 2Gene find turns soldier beetle defence into biotech opportunity 2Despite their thick skins, alligators and crocodiles are surprisingly touchy 2Despite their thick skins, alligators and crocodiles are surprisingly touchy 3
... system for fluorescent light due to small ... camera to detect low level light in ... disease research, gene expression, circadian rhythm, gels ... imager with a motor-driven camera inside the ...
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
...
Biology Products: